osimertinib
astrazeneca
['sclc', 'lcsm,(-blcsm)', 'nsclc']
#asco23 clinical science symposium on egfrmt nsclc: ph ii neoadj osi in resectable nsclc
- mpr 15%
- 89% had surgery
- interesting correlative science identifies rbm10 lof mutations assoc with non response #lcsm 
Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University